Patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations can experience improved prognosis when treated with EGFR-tyrosine kinase inhibitor [1, 2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.